Clinical progression of high-grade cervical intraepithelial neoplasia: Estimating the time to preclinical cervical cancer from doubly censored national registry data

American Journal of Epidemiology

Volumn 178, Issue 7, 2013, Pages 1161-1169

  Vink, Margaretha A ^a,b   Bogaards, Johannes A ^a,b   Van Kemenade, Folkert J ^a,b   De Melker, Hester E ^a   Meijer, Chris J L M ^b   Berkhof, Johannes ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cervical cancer; cervical intraepithelial neoplasia; disease progression; doubly censored data; human papillomavirus; mover stayer model; natural history; registries

Indexed keywords

CANCER; DATABASE; DISEASE INCIDENCE; EPIDEMIOLOGY; LESION; REPRODUCTIVE HEALTH; TUMOR; VACCINATION; VIRUS; WOMENS HEALTH;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; MAXIMUM LIKELIHOOD METHOD; NETHERLANDS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; STATISTICAL MODEL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WART VIRUS;

CERVICAL CANCER; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; DOUBLY CENSORED DATA; HUMAN PAPILLOMAVIRUS; MOVER-STAYER MODEL; NATURAL HISTORY; REGISTRIES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INCIDENCE; MIDDLE AGED; MODELS, STATISTICAL; PAPANICOLAOU TEST; PRECANCEROUS CONDITIONS; REGISTRIES; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

NETHERLANDS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84884920436     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwt077     Document Type: Article

References (45)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
2. Syrjnen K, Hakama M, Saarikoski S, et al. Prevalence, incidence and estimated life-Time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis. 1990;17(1):15-19.
3. Schiffman M,Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(5):368-383.
4. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731-738.
5. Woodman CB, Collins S,Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271): 1831-1836.
6. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992; 327(18):1272-1278.
7. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425-434.
8. Schiffman M, Rodrguez AC. Heterogeneity in CIN3 diagnosis. Lancet Oncol. 2008;9(5):404-406.
9. Sasieni P, Castanon A, Parik DM. How many cervical cancers are prevented by treatment of screen-detected disease in young women? Int J Cancer. 2009;124(2):461-464.
10. Van der Laan MJ, Jewell NP. The NPMLE for doubly censored current status data. Scand J Stat. 2001;28(3): 537-547.
11. De Kok IM, Van der Aa MA, Van Ballegooijen M, et al. Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? Int J Cancer. 2011;128(9): 2174-2181.
12. Van Oortmarssen GJ, Habbema JDF. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer. 1991;64(3):559-565.
13. Gustafsson L, Adami HO. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer. 1989;60(1):132-141.
14. Bos AB, Van Ballegooijen M, Van Oortmarssen GJ, et al. Non-progression of cervical intraepithelial neoplasia estimated from population-screening data. Br J Cancer. 1997;75(1): 124-130.
15. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9:119.
16. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomized controlled trial. Lancet Oncol. 2012;13(1):78-88.
17. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151(12): 1158-1171.
18. Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/19 vaccine. Int J Cancer. 2003;106(6):896-904.
19. Casparie M, Tiebosch ATMG, Burger G, et al. Pathology databanking and biobanking in the Netherlands: a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007; 29(1):19-24.
20. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3): 249-257.
21. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113(1):18-25.
22. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 2001;358(9295):1782-1783.
23. Efron B. Better bootstrap confidence intervals. J Am Stat Assoc. 1987;82(397):171-185.
24. Bogaards JA, Coup VMH, Xiridou M, et al. Long-Term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology. 2011;22(4):505-515.
25. van Ballegooijen M, Rebolj M, Essink-Bot ML, et al. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering [in Dutch]. Rotterdam, the Netherlands: Erasmus MC; 2006.
26. Gk M, Heideman DAM, Van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ. 2010;340:c1040.
27. Bulk S, Bulkmans NWJ, Berkhof J, et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and highrisk HPV testing at baseline and at 6-months. Int J Cancer. 2007;121(2):361-367.
28. Bulk S, Berkhof J, Bulkmans NWJ, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in the Netherlands. Br J Cancer. 2006; 94(1):171-175.
29. Zielinski GD, Snijders PJF, Rozendaal L, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer. 2001;85(3):398-404.
30. Wentzensen N,Walker J, Schiffman M, et al. Heterogeneity of high-grade cervical intraepithelial neoplasia related to HPV16: implications for natural history and management. Int J Cancer. 2013;132(1):148-154.
31. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008; 359(8):821-832.
32. Yen AM, Chen TH, Duffy SW, et al. Incorporating frailty in a multi-state model: application to disease natural history modelling of adenoma-carcinoma in the large bowel. Stat Methods Med Res. 2010;19(5):529-546.
33. Kocken M, Uijterwaal MH, de Vries AL, et al. High-risk human papillomavirus testing versus cytology in predicting post-Treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol. 2012;125(2): 500-507.
34. Van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, et al. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst. 2002;94(3):193-204.
35. Van Oortmarssen GJ, Habbema JDF. Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears. Int J Epidemiol. 1995; 24(2):300-307.
36. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med. 2007;45(2-3):93-106.
37. Bos AB, Rebolj M, Habbema JDF, et al. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer. 2006; 119(10):2372-2375.
38. Gk M, Rozendaal L, Berkhof J, et al. Cytology history preceding cervical cancer diagnosis: a regional analysis of 286 cases. Br J Cancer. 2011;104(4):685-692.
39. Coup VMH, Berkhof J, Bulkmans NWJ, et al. Agedependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer. 2008;98(3):646-651.
40. Berkhof J, Bulkmans NWJ, Bleeker MCG, et al. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1268-1273.
41. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
42. Kjr SK, Frederiksen K, Munk C, et al. Long-Term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19):1478-1488.
43. Coup VM, Bogaards JA, Meijer CJ, et al. Impact of vaccine protection against multiple HPV types on the costeffectiveness of cervical screening. Vaccine. 2012;30(10): 1813-1822.
44. Berkhof J, Coup VMH, Bogaards JA, et al. The health and economic effects of HPV DNA screening in the Netherlands. Int J Cancer. 2010;127(9):2147-2158.
45. Coup VMH, de Melker HE, Snijders PJF, et al. How to screen for cervical cancer after HPV16/18 vaccination in the Netherlands. Vaccine. 2009;27(37):5111-5119.